Resource Summary Report

Generated by NIF on Sep 16, 2026

Y-79

RRID:CVCL_1893
Type: Cell Line

Proper Citation

RRID:CVCL_1893

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1893

Proper Citation: RRID:CVCL_1893

Description: Cell line Y-79 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Retinoblastoma

Defining Citation: PMID:679190, PMID:1679230, PMID:2917337, PMID:3413073, PMID:3518877, PMID:4135597, PMID:6167750, PMID:6351622, PMID:7499444, PMID:7689221, PMID:18036396, PMID:18799932, PMID:19686387, PMID:20215515, PMID:21697133, PMID:23498719, PMID:25326674, PMID:27050416, PMID:27115612, PMID:29162051, PMID:29192327, PMID:30584916, PMID:32123578, PMID:32143590

Comments: Anecdotal: Named Y-79 because it was the result of the 79th attempt of a group at Yale to establish a retinoblastoma cell line., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Y-79

Synonyms: Y79, GM01232, GM01232E

Cross References: BTO:BTO_0002920, CLO:CLO_0009709, CLO:CLO_0030277, CLO:CLO_0051564, EFO:EFO_0002392, CLDB:cl4796, CLDB:cl4797, CLDB:cl4798, CLDB:cl4984, AddexBio:C0029001/4898, ArrayExpress:E-MTAB-38, ATCC:HTB-18, BCRC:60422, BCRJ:0380, BioSample:SAMN00803744, BioSample:SAMN01821607,

BioSample:SAMN03472733, BioSample:SAMN03473388, cancercelllines:CVCL_1893, Cell_Model_Passport:SIDM01395, ChEMBL-Cells:CHEMBL3308054, ChEMBL-Targets:CHEMBL613820, CLS:300382, Coriell:GM01232, Cosmic:688120, Cosmic:808507, Cosmic:1071899, Cosmic:1176623, DepMap:ACH-001295, DSMZ:ACC-246, DSMZCellDive:ACC-246, ECACC:86093003, FANTOM5_SSTAR:10475-106I7, GEO:GSM1250686, GEO:GSM1250688, GEO:GSM1486288, GEO:GSM2043882, IBRC:C11182, ICLC:HTL99029, IGRhCellID:Y79, JCRB:JCRB3020, JCRB:KURB2684, NCBI_Iran:C201, Progenetix:CVCL_1893, PubChem_Cell_line:CVCL_1893, RCB:RCB0427, RCB:RCB1645, Ubigene:YC-B015, Wikidata:Q54995129

ID: CVCL_1893

Record Creation Time: 20220427T221736+0000

Record Last Update: 20260913T010452+0000

Ratings and Alerts

No rating or validation information has been found for Y-79.

Warning: Discontinued: RCB; RCB0427
Anecdotal: Named Y-79 because it was the result of the 79th attempt of a group at Yale to establish a retinoblastoma cell line., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). Warning: Discontinued: JCRB; KURB2684
Anecdotal: Named Y-79 because it was the result of the 79th attempt of a group at Yale to establish a retinoblastoma cell line., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Gudenas BL, et al. (2026) A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies. Cancer cell, 44(4), 831.

Sujjitjoon J, et al. (2026) B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma. Scientific reports, 16(1), 4210.

Zhang Z, et al. (2025) The role of lactate metabolism in retinoblastoma tumorigenesis and ferroptosis resistance. Tissue & cell, 95, 102893.

Lindström L, et al. (2025) Targeting TUBG1 in RB1-negative tumors. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 39(5),

e70431.

Ryl T, et al. (2024) A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma. Communications biology, 7(1), 919.

Yin J, et al. (2024) Gentiopicroside inhibits retinoblastoma cell proliferation, invasion, and tumorigenesis in nude mice by suppressing the PI3K/AKT pathway. Naunyn-Schmiedeberg's archives of pharmacology, 397(2), 1003.

Noguchi Y, et al. (2024) In vivo CRISPR screening directly targeting testicular cells. Cell genomics, 4(3), 100510.

Wang Y, et al. (2024) Targeting ALDOA to modulate tumorigenesis and energy metabolism in retinoblastoma. iScience, 27(9), 110725.

Haase A, et al. (2024) New retinoblastoma (RB) drug delivery approaches: anti-tumor effect of atrial natriuretic peptide (ANP)-conjugated hyaluronic-acid-coated gold nanoparticles for intraocular treatment of chemoresistant RB. Molecular oncology.

Lunegova DA, et al. (2024) Antioxidant properties of the soluble carotenoprotein AstaP and its feasibility for retinal protection against oxidative stress. The FEBS journal.

Pearson JD, et al. (2024) Netrin-1 and UNC5B Cooperate with Integrins to Mediate YAP-Driven Cytostasis. Cancer research communications, 4(9), 2374.

Pascual-Pasto G, et al. (2024) Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(16), 3578.

Chittavanich P, et al. (2023) Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression. Molecular oncology.

Schmid V, et al. (2022) Retinoschisin and novel Na/K-ATPase interaction partners Kv2.1 and Kv8.2 define a growing protein complex at the inner segments of mammalian photoreceptors. Cellular and molecular life sciences : CMLS, 79(8), 448.

Zeng S, et al. (2022) Inhibiting the activation of MAPK (ERK1/2) in stressed Müller cells prevents photoreceptor degeneration. Theranostics, 12(15), 6705.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer cell, 39(8), 1115.

Hoshino A, et al. (2020) Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell, 182(4), 1044.

Zhang T, et al. (2019) Simvastatin protects photoreceptors from oxidative stress induced by all-trans-retinal, through the up-regulation of interphotoreceptor retinoid binding protein. British journal of pharmacology, 176(12), 2063.